After launching its Wegovy pill early this month, Novo Nordisk (NVO) has garnered 3,071 U.S. prescriptions for the oral GLP-1 agonist in the first four days of its commercial rollout, Reuters reported on Friday, citing data from Barclays analysts.
The actual number of prescriptions will be higher, as the findings only include the retail prescriptions for the once-daily pill and exclude those filled through Novo’s (NVO) direct-to-consumer platform, NovoCare Pharmacy.
The company launched the product at $149 per month for cash-paying customers on Jan. 5, and subsequently retailers such as Amazon (AMZN) joined the rollout.
The findings indicate the initial signs of how the Danish drugmaker is consolidating its first-mover advantage in the promising market for oral obesity drugs after the U.S. approved the pill in December, making it the first GLP-1 oral treatment licensed for obesity.
Lilly’s (LLY) oral weight loss pill, or forglipron, is currently under FDA priority review, with a decision expected by Apr. 10, according to internal documents seen by Reuters.